Paul A. Liberti, CEO and Chief Scientific Officer
A graduate of Columbia University’s Columbia College; Loyola University Chicago’s Stritch School of Medicine; Stevens Institute of Technology; post-doctoral work at: NJ College of Medicine/Thomas Jefferson Medical College (Immunochemistry); National Institute for Medical Research, Mill Hill, London (Cellular & Viral Immunology); Dr. Liberti was on the faculty of Thomas Jefferson Medical College for 16 years, rising from Assistant Professor to Full Professor in 5 years. A recipient of an NIH Career Development Award, he built a substantial National Institute of Health (NIH) funded research program and was Director of an Immunology Post-Doctoral Training Program funded by the National Institute for Allergy and Infectious Diseases (NIAID). A principal speaker at several international symposia, he is globally recognized for his work on the structure of antibody combing sites and on studies regarding of the role (if any) of antibody conformational changes induced by reaction with germs as well as subsequent reactions with the complement system following antibody recognition.
Following a successful academic career at Thomas Jefferson Medical College (Professor of Immunology/Physical Biochemistry), he founded (1984) and managed Immunicon Corp. (NASDAQ: IMMC), a biotechnology firm based in Huntingdon Valley, PA for 16 years. At Immunicon, he invented and developed: a broad spectrum of highly magnetic colloids for use in immunoassays and in cell diagnostics, novel high gradient quadrupole and hexapole separators as well as methods for immunoassays and cell selection. Dr. Liberti holds over 30 seminal U.S. patents in these areas. In addition to leading the R&D program, he played a key role in Business Development particularly in corporate partnering (in excess of $30MM with 5 major firms) and VC funding (completing 3 rounds for $55MM) as well as the management and strategy of Immunicon’s IP patent portfolio.
Based on his insights and discoveries on the exquisite ability of these systems to find “the needle in the haystack” as regards cells in complex systems, he steered Immunicon into rare cell analysis (cancer cells) and developed, with a substantial research team that he recruited, a cancer diagnostic platform technology he named “CELLSEARCH®.”
Immunicon Corp. was acquired by Johnson & Johnson in 2008 who in 2003 created a new SBU around Immunicon’s CELLSEARCH® product suite and technology, J&J’s Veridex division (later Janssen Diagnostics & Janssen Oncology). In 2004, Immunicon was named Nanotechnology IPO of the Year by Small Times magazine. Immunicon raised over a $100MM in private venture funding prior to its NASDAQ IPO in 2004 when it raised $155MM.
In 2009, the CELLSEARCH® Circulating Tumor Cell (CTC) Test was honored with the prestigious Prix Galien USA 2009 Award for Best Medical Technology. First awarded in the USA in 2009, the Prix Galien* recognizes the Best Medical, Biotechnology and Pharmaceutical Technology approved by the FDA in the past ten years. With over 8 Nobel Laureates on the 2009 Prix Galien’s committee, the Prix Galien is the Nobel Prize of the commercial medical and biotechnology fields.
* The Prix Galien USA committee judges which among the candidates, independent of any category, is the Best Pharmaceutical Agent (i.e. small molecule), is the Best Biotechnology Product and which is the Best Medical Technology approved by the FDA in the past ten years. As few as one or as many as three prizes may be awarded in each of these categories, and from time to time the committee may decide on awards hors prix. The prizes are awarded for breakthrough, successful products and agents that improve the human condition.
Ted L. Liberti, COO & EVP of Business Development
Ted L. Liberti, COO & EVP for Business Development, oversees BioMagnetic Solutions business development, finance and strategic partnering initiatives for: cell & gene therapy (CGT) clinical-scale cell selection systems (X-GRAFFE™), life science research market products (FEOSS™), biopharma and bioprocessing. Fluent with ferrofluid manufacture & technology, he is well versed in BioMagnetic Solutions' technologies, product development, product markets, manufacturing, IP, quality systems & the rapidly evolving CGT ecosystem for CAR-T cell and gene therapy (GT). He oversees BioMagnetic Solutions' intellectual property (IP) estate and patent filings that include over 7 PCT international patent applications for X-GRAFFE™ & FEOSS™ cell separation systems. He also oversees BioMagnetic Solutions' NIH SBIR applications to the NIH & the National Heart, Lung & Blood Institute (NHLBI) whose NIH SBIR funding has underwritten X-GRAFFE™ Clinical-Scale Cell Selection product development.
Ted holds a B.S. in Economics from Penn State University and an M.A. in Applied Economics from the University of Delaware. Ted completed doctoral research in economics, strategy & entrepreneurship at Penn State’s Smeal College of Business and Department of Economics. He holds an M.B.A. in international corporate strategy from the University of Delaware with high honors. Fluent in French, Ted started his career in international banking with JP Morgan Paris to learn first-hand about financial markets, investment banking and the French economy. Later with Immunicon Corp. (NASDAQ: IMMC), he helped drive Immunicon’s business development, business strategy, contract research projects & collaborations with: bioMérieux S.A., Guerbet S.A. and French academic groups in Paris & Lyon and advised on the valuation of Immunicon’s MRI contrast agent patents, leading to a $750,000 licensing arrangement with Sweden’s Nycomed Pharmaceuticals. From 2006 to 2012, he advised Ben Franklin Technology Partners’ (BFTP) portfolio of: life science, medical device and IT early-stage companies on: business development, marketing, finance and strategy.
Qiuyan Chen, Research and Development Scientist
Qiuyan Chen, MD, Ph.D., has an exceptional multidisciplinary background in the biosciences from the molecular to the clinical level. She completed her Ph.D. studies in molecular immunology at the Peking Union Medical College/Chinese Academy of Medical Sciences, and a Master’s degree in pathology focusing on tumor immunology at Medical College of Xian Jiaotong University where she also completed her medical degree. After initially practicing medicine, her passion to tumor immunology and problem solving capabilities drove her to dedicate herself to research in immune regulation and cancer biology. Upon completing postdoctoral training at the University of Pittsburgh, she joined the research faculty at Pennsylvania State University where she focused on understanding the role of monocytes during carcinogenesis, T and NKT cells in host defense as well as tumor clearance, and B cell differentiation and their mechanisms in terms of antigen presentation and immune response to vaccination and tumors.
Intrigued by the innovative and translational research and development that are in many areas related to her own interests of tumor immunology with creative problem solving, Dr. Chen joined BioMagnetic Solutions and works closely with Dr. Liberti to apply the company’s magnetic nanoparticle technology to create tools for immune cell therapy.
Dr. Chen leads the research and development team, oversees product development and manufacture for highly sophisticated cell separations.
Christine M. Corl, Director of Quality Assurance and Regulatory
Christine Corl, M.S, has a background that spans basic and translational/clinical research. She completed her M.S. in pathobiology at Penn State University with a focus on immunology/inflammation. Upon completing her degree, she spent ten years at Michigan State University as a research associate focusing on bovine mastitis, lipid metabolism, and oxidant stress. Chris later joined the Clinical Cell and Vaccine Production Facility within the Center for Cellular Immunotherapy at the University of Pennsylvania where she gained significant quality systems experience in a cGMP environment. As the quality control validation manager, Chris played an integral role in improving analytical validation methods, developing/improving standard operating procedures, developing flow cytometry review guidelines, reviewing data for release, and reviewing deviations/corrective or preventative actions.
Upon returning to her family’s farm in Central PA, Chris joined BioMagnetic Solutions to develop the quality management system and lead the effort to begin cGMP manufacturing.
Richard A. O’Leary, EVP of Human Resources and Administration
Richard A. O’Leary, Ed.D., oversees BioMagnetic Solutions’ HR strategy and planning. With BioMagnetic Solutions’ management team, he helps oversee the company’s overall strategic and corporate direction. Dr. O’Leary is President of O’Leary and Associates that specializes in aligning Human Capital Practices with Organizational Strategy. He brings deep experience with growing companies, both large and small, and an exceptional background leading global change and strategic growth initiatives. Most recently, he was the corporate vice-president of Human Resources for Hardinge, Hopkins Manufacturing and Milacron LLC. Prior to that, he served as corporate vice-president of Human Resources and Administration for Iris International. He also held senior level HR positions with Corning Incorporated (as Global Director of International Regions and their Global Technology Community), Cytometrics (Corporate Vice President of HR), Owens Corning (Global Director Talent Management and Organizational Effectiveness), and Public Service Electric and Gas. During his career, he also served with the Delaware Air National Guard State Staff for over 25 years, retiring as a Clinical Psychologist and Human Relations Officer, Lieutenant Colonel, USAF. Richard’s extensive educational background includes a B.A. in Sociology and a Master’s degree in College Counseling, both from the University of Delaware; he also has a doctorate in Counseling Psychology, from Western Michigan University. He serves as an Adjunct faculty member at Rowen University of Medicine teaching strategy and leadership. He is also a senior fellow with the Best Practice Institute.